(Q38137829)

29 August 2017

title

Imaging EGFR and HER2 by PET and SPECT: a review (English)

1 reference

29 August 2017

Emily B Corcoran

1

1 reference

29 August 2017

Robert N Hanson

series ordinal

2

1 reference

29 August 2017

publication date

29 August 2013

1 reference

Medicinal Research Reviews

29 August 2017

published in

1 reference

29 August 2017

volume

34

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

596-643

1 reference

Untangling the ErbB signalling network

29 August 2017

cites work

1 reference

An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology

21 January 2018

1 reference

Testing for HER2 in breast cancer

21 January 2018

1 reference

Epidermal growth factor receptor: a promising target in solid tumours

21 January 2018

1 reference

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Epidermal growth factor receptor biology in head and neck cancer

21 January 2018

1 reference

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

21 January 2018

1 reference

PET versus SPECT: strengths, limitations and challenges

21 January 2018

1 reference

Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.

21 January 2018

1 reference

[11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma

21 January 2018

1 reference

Automated synthesis of [18F]gefitinib on a modular system.

21 January 2018

1 reference

Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

21 January 2018

1 reference

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

21 January 2018

1 reference

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

21 January 2018

1 reference

In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.

21 January 2018

1 reference

Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.

21 January 2018

1 reference

Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.

21 January 2018

1 reference

Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.

21 January 2018

1 reference

Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer

21 January 2018

1 reference

Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents

21 January 2018

1 reference

Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging

21 January 2018

1 reference

Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.

21 January 2018

1 reference

A quinazoline-derivative DOTA-type gallium(III) complex for targeting epidermal growth factor receptors: synthesis, characterisation and biological studies

21 January 2018

1 reference

Synthesis, characterization and biological evaluation of In(III) complexes anchored by DOTA-like chelators bearing a quinazoline moiety

21 January 2018

1 reference

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity

21 January 2018

1 reference

Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.

21 January 2018

1 reference

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors

21 January 2018

1 reference

Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors

21 January 2018

1 reference

Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer

21 January 2018

1 reference

High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors

21 January 2018

1 reference

A fully automated two-step synthesis of an (18)F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors

21 January 2018

1 reference

Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.

21 January 2018

1 reference

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT

21 January 2018

1 reference

Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

21 January 2018

1 reference

Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats.

21 January 2018

1 reference

PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model

21 January 2018

1 reference

Preclinical characterisation of 111In-DTPA-trastuzumab.

21 January 2018

1 reference

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.

21 January 2018

1 reference

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab

21 January 2018

1 reference

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging

21 January 2018

1 reference

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.

21 January 2018

1 reference

Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry

21 January 2018

1 reference

Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer.

21 January 2018

1 reference

(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft

21 January 2018

1 reference

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.

21 January 2018

1 reference

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

21 January 2018

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts

21 January 2018

1 reference

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

21 January 2018

1 reference

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma

21 January 2018

1 reference

In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies

21 January 2018

1 reference

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.

21 January 2018

1 reference

Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

21 January 2018

1 reference

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

21 January 2018

1 reference

Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer

21 January 2018

1 reference

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent

21 January 2018

1 reference

Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma

21 January 2018

1 reference

PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab

21 January 2018

1 reference

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models

21 January 2018

1 reference

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

21 January 2018

1 reference

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor

21 January 2018

1 reference

CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

21 January 2018

1 reference

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

21 January 2018

1 reference

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

21 January 2018

1 reference

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

21 January 2018

1 reference

A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.

21 January 2018

1 reference

Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates

21 January 2018

1 reference

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

21 January 2018

1 reference

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment

21 January 2018

1 reference

Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy

21 January 2018

1 reference

In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics

21 January 2018

1 reference

Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.

21 January 2018

1 reference

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

21 January 2018

1 reference

(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

21 January 2018

1 reference

Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.

21 January 2018

1 reference

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

21 January 2018

1 reference

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

21 January 2018

1 reference

Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.

21 January 2018

1 reference

[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

21 January 2018

1 reference

Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules

21 January 2018

1 reference

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model

21 January 2018

1 reference

Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting

21 January 2018

1 reference

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

21 January 2018

1 reference

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

21 January 2018

1 reference

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

21 January 2018

1 reference

Engineered two-helix small proteins for molecular recognition

21 January 2018

1 reference

In vivo targeting of HER2-positive tumor using 2-helix affibody molecules

21 January 2018

1 reference

A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression

21 January 2018

1 reference

A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor

21 January 2018

1 reference

Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules

21 January 2018

1 reference

64Cu-labeled affibody molecules for imaging of HER2 expressing tumors

21 January 2018

1 reference

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer

21 January 2018

1 reference

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount

21 January 2018

1 reference

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

21 January 2018

1 reference

Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein

21 January 2018

1 reference

PET of EGFR expression with an 18F-labeled affibody molecule

21 January 2018

1 reference

Camelid immunoglobulins and nanobody technology.

21 January 2018

1 reference

Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.

21 January 2018

1 reference

Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.

21 January 2018

1 reference

Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.

21 January 2018

1 reference

SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression

21 January 2018

1 reference

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

21 January 2018

1 reference

Molecular imaging of EGFR: it's time to go beyond receptor expression.

21 January 2018

1 reference

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.21299

1 reference

29 August 2017

1 reference